There is scant evidence describing antimicrobial usage in companion animal primary-care veterinary practices in the UK. The use of antimicrobials in dogs and cats was quantified using data extracted from 374 veterinary practices participating in VetCompass. The frequency and quantity of systemic antimicrobial usage was described.
Introduction

1
There is scant evidence describing the extent of antimicrobial (AM) usage in companion animal species 2 attending veterinary practices in the United Kingdom and these species have received limited 3 attention as a reservoir of antimicrobial resistance (AMR). AM usage in companion animals is 4 potentially of considerable importance to the efforts to control AMR, a growing problem in human 5 and animal medicine (Prescott 2008) , since companion animals are often in close contact with the 6 human population (Guardabassi and others 2004; Cain 2013 ). Central to addressing AMR in 7 companion animal veterinary practice is the need for a clear understanding of current levels and 8 patterns of AM usage in veterinary practice. The frequency of AM use in companion animals may be 9
growing as a result of increased population, better availability of veterinary services and use of 10 antimicrobials for a range of health conditions (Guardabassi and others 2004) . In Norway, there were 11 338 prescriptions per 1000 dogs per year in 2004, increasing by 13.3% by 2008 (Kvaale and others 12 2013 ). Previous studies have described the use of AMs in UK companion animal practices (Radford 13 and others 2011; Mateus and others 2011) and agents most frequently used were amoxicillin-14 clavulanate, cephalexin, clindamycin and cefovecin (Radford and others 2011; Mateus and others 15 2011; Summers and others 2012). However these studies were limited by small sample sizes, and were 16 therefore not able to fully quantify AM usage across the UK. Annual antibiotic sales data have been 17 used as a proxy for the assessment of antibiotic use (VMD 2014), with the recognition that sales data 18 are likely to overestimate actual usage and provide little information on the species and dosages used. 19 There is a need to develop ongoing systematic capture of AM usage data by either utilising existing 20 technologies or creating new systems to improve data capture in order to more fully estimate the 21 scale of usage and potential role of companion animals in AMR and zoonotic transmission. There may 22 be geographic differences in patterns of usage, for example in urban versus rural areas, with 23 potentially important implications for tackling AMR (Kvaale and others 2013). A greater understanding 24 of the absolute quantities dispensed and administered in companion animal practice would aid policy 25 makers in their assessment of the relative contribution of this veterinary subgroup to overall AM levels 26 of usage and AMR. 27
In order to establish a current baseline for AM usage in the UK, this study aimed to characterise the 28 frequency and quantity of AM usage in cats and dogs over a two-year study period in a large sample 29 of practices participating with the VetCompass Programme (www.rvc.ac.uk/VetCompass), which 30 collects de-identified clinical data from veterinary practices across the UK. The objectives of the study 31 were to identify the frequency of AM events and the respective quantities of AM product as indicators 32 of the magnitude of usage, especially those classified as critically important in human medicine, and 33 to evaluate variation in spatial distribution in AM usage across the UK. These data can be used to 34 support policy on AM usage in companion animal species. 35
Methods
36
The study was approved by the 
Results
24
De-identified clinical data from 374 UK companion animal practices were accessed via the VetCompass 25
Programme. Participating practices comprised principally of two large practice groups as well as 26 several independent practices and reflected a geographically widely dispersed cohort of practices. 27 Three clinics (0.8%) did not have a usable postcode and were therefore not included in any map figures 28 throughout the report, but were included for all other AM event and quantity analyses. The majority 29 of practices were located in England, particularly the Midlands and East England and few practices 30 were located in Northern Scotland. In total across the practices, 963,463 dogs and 594,812 cats had 31 at least one EPR recorded within the two-year period and these animals comprised the study 32 population, shown in Figure 1 . participating practices came from all regions of the UK, and although the data derived principally from 16 two large practice groups, a number of independent practices were also involved and therefore the 17 data were likely to give a reliable example of the level of usage across UK companion animal general 18 practice. Emergency and referral hospitals or charity-based practices were not included in this study, 19 and thus the level of AM usage reported here may be less generalisable to those practice types. The 20 representativeness of data in the current study according to the total UK dog and cat population is 21 difficult to determine, and although the values are accurate in terms of AM events per animals 22 attending study practices, the data may over-estimate usage per animal in the population, due to the 23 absence of animals that are not registered at a veterinary practice or that did not attend a veterinary 24 practice within the two-year study period. For example, it is known that not all dogs and cats are 25 registered with veterinary practices; Asher and others (2011) reported that approximately 17% of 26 owners in the public survey had not registered their dog with a veterinary practice. 27
In the current study, there was widespread use of broad-spectrum agents such as aminopenicillins 28 plus clavulanic acid, cephalosporins and fluoroquinolones across the participating VetCompass 29 practices for both dogs and cats, in agreement with previous UK data (Radford and others 2011; 30 Mateus and others 2011) and data from other European countries e.g. France (Anses, 2014) . Many of 31 these agents, and up to 81% of the AM events together across both species, were considered to be 32 critically important for human health (WHO 2012), including those deemed of highest importance 33 (approximately 40% of AMs used). This raises concerns about potential horizontal transmission of 34 resistance determinants and resistant bacteria to CIAs through companion animals. reported 30% and 15% of antibiotics used for dogs and cats, respectively, in Europe were highest 38 importance CIAs, with more AMs prescribed being considered of lower importance (e.g. tetracylines, 39
De Briyne and others 2014), suggesting that there may be differences in prescribing behaviour 40 between EU member states. Only a small proportion of veterinarians were surveyed and the 41 methodological differences in how these data were collected may also contribute to these differing 42 results. 43
Antimicrobial usage patterns differed substantially between dogs and cats in the current study. 44 Administration of AM agents used for dogs was principally by oral tablet (81%) whereas the majority 45 of AM agents for cats were administered via the injectable method (55%). This likely reflects general 46 differences in methods of administering medicines between the species, with oral tablets being 1 perceived as more difficult to effectively administer in cats (Traas and others 2010). Dogs received 2 proportionally more aminopenicillin-types (54% versus 46%) and nitromidazoles (11% versus 5%) than 3 cats. Cats received proportionally higher usage of 3 rd generation cephalosporins, critically important 4 agents of highest importance, and this was largely explained by the more frequent use of cefovecin 5 injectable products in cats (54% of total cat events versus 1.31% of dogs). This is in agreement with 6 other studies, e.g. Murphy and others (2012) found higher use of cefovecin in cats and amoxicillin-7 clavulanic acid in dogs. A higher frequency of cats received a single AM event over the two year period, 8 69% of cats versus 58% of dogs. However, the range of counts for repeat AM events was more diverse 9 for cats. These differences may reflect differences in the deliverance of AMs for the two species, e.g. 10 preference for a single long-lasting injectable in cats. No attempt was made to evaluate the underlying 11 disorders requiring AMs in these animals, or the clinical appropriateness of dosages, though this is 12 possible with further analysis of the data contained with VetCompass. Murphy and others (2012) 13 showed overuse of cefovecin and fluoroquinolones for the treatment of common diseases in dogs and 14 cats (feline upper respiratory tract disease, feline lower urinary tract disease and canine infectious 15 tracheobronchitis) in Ontario, where 67-74% of disease events were treated with antimicrobials, and 16 65% of antimicrobials prescribed were beta-lactams. 17
For both dogs and cats, spatial analysis suggested that there was a trend towards higher AM event 18 frequency in South East England, South Wales, and South West Scotland, with significant spatial 19 clustering observed in dog but not cat AM usage overall, though the latter lack of statistical 20 significance may have reflected the smaller sample size for cats. Spatial distribution accounted for 21 variation in animal density distributions and so any differences identified were unlikely to be explained 22 by regional differences in the numbers of animals attending practices. Possible explanations for the 23 geographical variation seen could be differences in animal demographics, associated diseases and/or 24 regional variations in prescribing and administering behaviours of the veterinary practices. The spatial 25
clustering undertaken was exploratory only in nature and any underlying reasons for differences in 26 regional distribution of AM events would need to be investigated further. Similar regional differences 27 in AM prescriptions were described in Norway (Kvaale and others 2013), although here, the 28 differences were likely to correspond to the density of dogs and veterinary clinics. Geographical 29 differences in AMR have also been reported; dogs in an urban habitat had a higher risk of carrying 30 isolates resistant to methicillin and other antimicrobials compared with dogs in a rural environment 31 (Huerta and others 2011). Such differences may in part be related to differences in AM usage, 32 exposure to other sources of AMR and/or awareness of regional resistance patterns. 
Conclusions
44
Overall, approximately a quarter of dogs and cats attending veterinary practices in the UK received at 45 least one AM event over the two-year period 2012-2014. Dogs mainly received oral tablets whilst cats 46 had AMs administered mainly as injectable preparations. The total AM quantity, by weight of active 1 ingredient, was estimated to be 1473Kg for dogs and 58Kg for cats. In particular, the most common 2 agents used for cats and dogs were amino-penicillin-types and cephalosporins. Of the AM events, 60% 3 in dogs and 81% in cats were of AMs classified as critically important (CIAs) to human health by the 4 WHO, and this may be important to consider when addressing companion animals as a potential 5 source or reservoir for AMR in humans. These findings can provide a baseline for AM usage in 6 companion animals in the UK, and can support continued surveillance of AM usage and investigation 7 of the role of companion animal veterinary practices in AMR. 8
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